Grande Group Limited (GRAN)

Blueprint Medicines Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Revenue	4.34	4.53	3.87
Revenue Growth (YoY)	-4.20%	17.00%	-
Cost of Revenue	1.02	1.52	1.55
Gross Profit	3.32	3.01	2.32
Selling, General & Admin	1.42	0.89	0.89
Operating Expenses	1.42	0.89	0.89
Operating Income	1.9	2.12	1.43
Interest & Investment Income	0.01	0.01	0
EBT Excluding Unusual Items	1.91	2.13	1.44
Other Unusual Items	0	-	0.07
Pretax Income	1.91	2.13	1.5
Income Tax Expense	0.29	0.33	0.22
Net Income	1.62	1.8	1.28
Net Income to Common	1.62	1.8	1.28
Net Income Growth	-9.95%	40.56%	-
Shares Outstanding (Basic)	23	10	10
Shares Outstanding (Diluted)	23	10	10
Shares Change (YoY)	127.50%	-	-
EPS (Basic)	0.07	0.18	0.13
EPS (Diluted)	0.07	0.18	0.13
EPS Growth	-60.42%	40.56%	-
Free Cash Flow	0.65	1.16	0.23
Free Cash Flow Per Share	0.03	0.12	0.02
Gross Margin	76.50%	66.46%	60.03%
Operating Margin	43.82%	46.87%	37.00%
Profit Margin	37.32%	39.70%	33.05%
Free Cash Flow Margin	15.10%	25.56%	5.92%
EBITDA	1.92	2.14	1.47
EBITDA Margin	44.25%	47.32%	37.89%
D&A For EBITDA	0.02	0.02	0.03
EBIT	1.9	2.12	1.43
EBIT Margin	43.82%	46.87%	37.00%
Effective Tax Rate	15.38%	15.67%	14.83%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q